Brodalumab in the treatment of psoriatic arthritis – the latest reports

Psoriatic arthritis is a chronic inflammatory disease that can lead to disability and significantly reduce the quality of life. Biological drugs are becoming increasingly important in the treatment of psoriatic arthritis. The purpose of this article is to introduce readers to the properties of brodalumab, which is a fully human IgG2 monoclonal antibody. The action of brodalumab is multidirectional - it improves the clinical condition of the skin, joints and entheses. For these reasons, it is worth reading the results of phase III studies on the use of brodalumab in PsA, which were published at the end of October 2020.

REFERENCES (8)

EMA. Kyntheum summary of product characteristics. Available: https://www.ema.europa.eu/docu... [Accessed 21.02.2021].

Google Scholar

Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012; 132: 2466–2469, DOI: 10.1038/jid.2012.163.

CrossRef

Google Scholar

Kyowa Kirin. LUMICEF® Approved in Japan, 2016. Available: https://www.kyowakirin. co m/media_center/news_releases/ 2016/e20160704_01.html.

Google Scholar

Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370: 2295–2306, DOI: 10.1056/NEJMoa1315231.

CrossRef

Google Scholar

Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis 2021; 80: 185–193, DOI: 10.1136/annrheumdis-2019-216835.

CrossRef

Google Scholar

Sawyer L, Fotheringham I, Wright E, et al. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network metaanalysis. J Dermatolog Treat 2018; 29: 557–568, DOI: 10.1080/ 09546634.2018.1427205.

Google Scholar

Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci 2020; 21: 1690, DOI: 10.3390/ijms21051690.

CrossRef

Google Scholar

Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273–286, DOI: 10.1111/bjd.14493.

CrossRef

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Submit your paper

eISSN:	2084-9834
ISSN:	0034-6233